| GC32977-5mg |
|
1616287-82-1 |
|
0 |
C22H21Cl2N3O3 |
|
|
|
| GC32977-10mM(1mLinDMSO) |
|
1616287-82-1 |
|
0 |
C22H21Cl2N3O3 |
|
|
|
| GC32976-2g |
|
1835705-59-3 |
E3 ligase Ligand-Linker Conjugates 9
|
0 |
C40H63ClN4O10S |
|
|
|
| GC32976-1g |
|
1835705-59-3 |
E3 ligase Ligand-Linker Conjugates 9
|
0 |
C40H63ClN4O10S |
|
|
|
| GC32976-500mg |
|
1835705-59-3 |
E3 ligase Ligand-Linker Conjugates 9
|
0 |
C40H63ClN4O10S |
|
|
|
| GC32976-100mg |
|
1835705-59-3 |
E3 ligase Ligand-Linker Conjugates 9
|
0 |
C40H63ClN4O10S |
|
|
|
| GC32975-500mg |
|
6112-76-1 |
|
0 |
C5H6N4OS |
|
|
|
| GC32975-100mg |
|
6112-76-1 |
|
0 |
C5H6N4OS |
|
|
|
| GC32975-50mg |
|
6112-76-1 |
|
0 |
C5H6N4OS |
|
|
|
| GC32975-10mM(1mLinDMSO) |
|
6112-76-1 |
|
0 |
C5H6N4OS |
|
|
|
| GC32974-50mg |
|
1702967-37-0 |
Vipivotide tetraxetan (PSMA-617)
|
0 |
C49H71N9O16 |
|
|
|
| GC32974-25mg |
|
1702967-37-0 |
Vipivotide tetraxetan (PSMA-617)
|
0 |
C49H71N9O16 |
|
|
|
| GC32974-10mg |
|
1702967-37-0 |
Vipivotide tetraxetan (PSMA-617)
|
0 |
C49H71N9O16 |
|
|
|
| GC32974-5mg |
|
1702967-37-0 |
Vipivotide tetraxetan (PSMA-617)
|
0 |
C49H71N9O16 |
|
|
|
| GC32974-1mg |
|
1702967-37-0 |
Vipivotide tetraxetan (PSMA-617)
|
0 |
C49H71N9O16 |
|
|
|
| GC32974-10mM(1mLinDMSO) |
|
1702967-37-0 |
Vipivotide tetraxetan (PSMA-617)
|
0 |
C49H71N9O16 |
|
|
|
| GC32973-100mg |
|
522606-67-3 |
SID 3712249 (MiR-544 Inhibitor 1)
|
0 |
C17H21N7 |
|
|
|
| GC32973-50mg |
|
522606-67-3 |
SID 3712249 (MiR-544 Inhibitor 1)
|
0 |
C17H21N7 |
|
|
|
| GC32973-25mg |
|
522606-67-3 |
SID 3712249 (MiR-544 Inhibitor 1)
|
0 |
C17H21N7 |
|
|
|
| GC32973-10mg |
|
522606-67-3 |
SID 3712249 (MiR-544 Inhibitor 1)
|
0 |
C17H21N7 |
|
|
|
